After more than two years of negotiation, the EU’s pharmaceutical legislation reform has a settled text. The Council and the European Parliament reached political agreement on the ‘pharma package’ in December 2025, and the compromise texts of the new Regulation and Directive were published in March 2026. Formal adoption and publication in the Official Journal are the remaining procedural steps. For marketing authorisation holders, the strategic question has shifted: it is no longer what the rules will say, but what to do in the runway before they apply.
What the agreed text settles
The package is the most substantial overhaul of EU pharmaceutical law in two decades, replacing the framework that has governed medicines since 2004. Several provisions matter immediately for planning:
- Regulatory protection. A new medicine benefits from an eight-year data protection period, plus one year of market protection. That market protection may be extended by a further year for innovative medicines meeting two of three specified conditions.
- Security of supply. A provision introduced by the Council allows Member States to require companies benefiting from regulatory protection to supply medicines in quantities sufficient to meet patient needs. Safeguards were added during negotiation to clarify the obligations on both companies and Member States, and to prevent the provision being used as a route to parallel trade.
- The Bolar exemption. The exemption permitting the studies and trials needed for day-one generic and biosimilar availability has been clarified, and its scope extended to cover submissions for procurement tenders.
- Antimicrobial resistance. A transferable exclusivity voucher will grant developers of priority antibiotics one additional year of market protection on a product of their choosing. A ‘blockbuster clause’ prevents the voucher being applied to products with annual gross sales above €490 million over the preceding four years.
The runway is shorter than it looks
Both instruments enter into force twenty days after publication in the Official Journal. The Regulation then becomes applicable after a transition period, and Member States have a corresponding window to transpose the Directive into national law. Two years sounds generous until it is set against the work involved: reviewing exclusivity assumptions across a portfolio, revisiting lifecycle plans built on the previous protection formula, and tracking twenty-seven separate transpositions.
For companies operating in Greece, the national transposition will matter as much as the EU text. How the Greek authorities implement supply obligations, and how those interact with existing pricing and reimbursement mechanisms, will shape the practical burden.
What to do in the meantime
- Re-model exclusivity. Products whose commercial case was built on the previous protection assumptions should be reassessed against the agreed formula, including whether the conditional extensions are realistically achievable.
- Map supply exposure. Identify which products in your portfolio could fall within the scope of the new supply provisions, and what evidence of adequate supply you would be able to produce.
- Watch the transposition, not just the Directive. National implementation is where the operational detail will land.
- Do not rebuild dossiers yet. The text is settled but not yet published; premature restructuring risks wasted effort.
How PQRA helps
PQRA helps pharmaceutical companies translate the pharma package from legislative text into a concrete plan. We assess portfolio exposure under the new protection framework, review lifecycle and submission strategies against the agreed provisions, and monitor Greek transposition so that national requirements are anticipated rather than discovered. Where products fall within scope of the supply provisions, we help build the documentation that demonstrates compliance.
The reform rewards companies that start planning before the obligations bite. Talk to PQRA about what the pharma package means for your portfolio.
No responses yet